Confronto
Follistatin (FST) vs. Hexarelin
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Crescita
Crescita
N. CAS
122956-17-2
140703-51-1
Peso molecolare
35000 g/mol
887.05 g/mol
Emivita
nessun dato
0.9 h
Sequenza
Glykoprotein, ~315 Aminosäuren in der zirkulierenden Hauptform (Sequenz isoformabhängig, kein einheitliches kurzes Peptid)His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2Meccanismo d'azione
Follistatin (FST)
Follistatin binds with high affinity to activin and to myostatin (GDF-8), as well as related TGF-β ligands such as GDF-11 and some BMPs, preventing their binding to the activin type-II receptors. Myostatin is a negative regulator of skeletal muscle mass; by sequestering myostatin, its growth-inhibiting signalling is removed (de-repression). Because follistatin additionally neutralises activin, it acts on several muscle-inhibiting pathways at once — in animal models this produced greater muscle gain than knocking out myostatin alone. Several isoforms exist (including FST-288 and FST-315) that differ in tissue binding via heparan sulfate. The FST344 variant used in gene therapy was chosen to reduce binding to off-target structures.
Hexarelin
Hexarelin is a synthetic analog of the GHRP-6 family binding both the GH secretagogue receptor (GHSR-1a) and CD36. GHSR activation in the pituitary releases pulsatile growth hormone. Via CD36 in endothelium and myocardium, cardioprotective effects have been described in animal studies.
Base di evidenze
Evidenza più alta
Studio sull'uomo
Studio sull'uomo
Studi
4
4
di cui sull'uomo
1
3
Effetti registrati
4
3
Contraddizioni aperte
1
0
Eventi avversi documentati
1
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Follistatin (FST) and Hexarelin?
- Follistatin (FST) is classified as "Crescita", while Hexarelin is classified as "Crescita". Follistatin (FST): Follistatin is an endogenous glycosylated binding protein (~35 kDa, considerably larger than typical peptides) that binds and neutralises members of the TGF-β superfamily, including activin and myostatin (GDF-8). In animal models, raising follistatin de-represses muscle growth. Clinically it has been studied mainly via AAV gene therapy (FS344) in muscular dystrophies. Follistatin is not an approved drug; human efficacy and safety data are limited and stem mostly from early gene-therapy trials and preclinical research. A 'follistatin-344' product is sold on the grey market, the identity and purity of which cannot be verified without analytics. Hexarelin: Synthetic hexapeptide of the growth-hormone secretagogue (GHRP) family. In the 1990s investigated as an acromegaly diagnostic and for GH deficiency. Not an approved medicine. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Follistatin (FST) or Hexarelin?
- The highest available evidence level is "Studio sull'uomo" for Follistatin (FST) and "Studio sull'uomo" for Hexarelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Follistatin (FST) and Hexarelin in Germany and the United States?
- Germania: Follistatin (FST) — Non approvato, Hexarelin — Non approvato. Stati Uniti: Follistatin (FST) — Non approvato, Hexarelin — Non approvato. These are factual summaries with source and review date on the individual pages.